^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Purinergic receptor P2Y12 inhibitor

    Related drugs:
    3d
    CAPTIVA: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (clinicaltrials.gov)
    P3, N=1683, Recruiting, University of Florida | Active, not recruiting --> Recruiting
    Enrollment open
    5d
    REPERFUSE: REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (clinicaltrials.gov)
    P3, N=368, Recruiting, Fondation Ophtalmologique Adolphe de Rothschild | Trial completion date: Jan 2027 --> Sep 2030 | Trial primary completion date: Mar 2026 --> Mar 2030
    Trial completion date • Trial primary completion date
    5d
    Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. (clinicaltrials.gov)
    P1, N=24, Completed, Laboratorios Silanes S.A. de C.V.
    New P1 trial
    |
    aspirin
    9d
    Drug repurposing of ticagrelor suppresses renal cell carcinoma growth by blockading the EGFR/PI3K/AKT axis. (PubMed, Ann Med)
    Mechanistically, the EGFR/PI3K/AKT pathway was identified as the key mediator of ticagrelor's antitumor activity in RCC. Ticagrelor exerts anti-RCC effects via blockade of the EGFR/PI3K/AKT signaling axis, highlighting its translational potential and positioning this pathway as a therapeutic target and possible biomarker in RCC.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    16d
    PANTHEON: Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (clinicaltrials.gov)
    P3, N=2570, Recruiting, Montreal Heart Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    aspirin
    18d
    Cangrelor in endovascular stroke treatment with emergent carotid artery stenting (CANCAS) (2025-521564-35-00)
    P1/2, N=50, Recruiting, Medical University Of Graz
    New P1/2 trial
    26d
    ATTEMPT: Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (clinicaltrials.gov)
    P4, N=3500, Recruiting, Samsung Medical Center | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    30d
    Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (clinicaltrials.gov)
    P4, N=50, Recruiting, University of Florida | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    1m
    TAVR-ELECTRO: Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Chinese Academy of Medical Sciences, Fuwai Hospital
    New trial
    1m
    CLOPI-SNAP: Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia (clinicaltrials.gov)
    P2, N=230, Not yet recruiting, Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
    New P2 trial
    1m
    Real-world Study on Clinical Characteristics and Risk Factors of Ticagrelor-related Dyspnea (ChiCTR2600116220)
    P=N/A, N=5000, Not yet recruiting, Chinese Academy of Medical Sciences Peking Union Medical College TEDA International Cardiovascular Hospital; Chinese Academy of Medical Sciences Pekin
    New trial
    1m
    Comparative Study of Treatment Strategies for Migraine in Patients with Patent Foramen Ovale (PFO): A Multicenter Randomized Controlled Trial of Transcatheter Closure versus Medical Therapy (ChiCTR2600115896)
    P=N/A, N=150, Recruiting, The Seventh Affiliated Hospital Sun Yat-sen University; The?Seventh?Affiliated?Hospital?Sun?Yat-sen?University
    New trial
    |
    aspirin